八味肾气丸合八正散加减对中老年反复发作性尿路感染的调节作用

严旭东; 黄超; 杨玲

doi:10.13422/j.cnki.syfjx.20181736

您当前的位置：

首页 >

文章列表页 >

八味肾气丸合八正散加减对中老年反复发作性尿路感染的调节作用

临床 | 更新时间：2024-01-04

- 八味肾气丸合八正散加减对中老年反复发作性尿路感染的调节作用
- Regulation Effect of Syndrome Differentiation and Treatment of Bawei Shenqi Wan Combined with Bazhengsan in Patients with Recurrent Urinary Tract Infection and Old Age
- 中国实验方剂学杂志 2018年24卷第17期页码：195-200
- 作者机构：
- 作者简介：
- 基金信息：
  
  四川卫生厅科技计划项目（130458）
- DOI：10.13422/j.cnki.syfjx.20181736
  中图分类号： R277.5
- 纸质出版日期：2018
- 稿件说明：
移动端阅览
严旭东, 黄超, 杨玲. 八味肾气丸合八正散加减对中老年反复发作性尿路感染的调节作用[J]. 中国实验方剂学杂志, 2018,24(17):195-200.

YAN Xu-dong, HUANG Chao, YANG Ling. Regulation Effect of Syndrome Differentiation and Treatment of Bawei Shenqi Wan Combined with Bazhengsan in Patients with Recurrent Urinary Tract Infection and Old Age[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(17): 195-200.
严旭东, 黄超, 杨玲. 八味肾气丸合八正散加减对中老年反复发作性尿路感染的调节作用[J]. 中国实验方剂学杂志, 2018,24(17):195-200. DOI： 10.13422/j.cnki.syfjx.20181736.

YAN Xu-dong, HUANG Chao, YANG Ling. Regulation Effect of Syndrome Differentiation and Treatment of Bawei Shenqi Wan Combined with Bazhengsan in Patients with Recurrent Urinary Tract Infection and Old Age[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(17): 195-200. DOI： 10.13422/j.cnki.syfjx.20181736.

摘要

目的：观察八味肾气丸合八正散加减治疗中老年反复发作性尿路感染（RUTI）的临床疗效及对免疫功能和炎症因子的影响。方法：将140例患者，按区组随机分为观察组和对照组各70例。对照组口服盐酸左氧氟沙星片，0.2 g/次，2次/d。连续治疗2周，尿培养阴性后采用头孢氨苄甲氧苄啶胶囊，0.25 g·d-1，睡前服用。观察组在对照组治疗的基础上加用八味肾气丸合八正散加减内服，1剂/d。两组疗程均连续治疗12周。进行治疗前后主要临床症状和生活质量评分；记录6个月内的复发情况；检测治疗前后α1-微球蛋白（α1-MG）和β2-微球蛋白（β2-MG），尿N-乙酰-β-氨基葡萄糖苷酶（NAG）水平；检测治疗前后T细胞亚群（CD3+，CD4+，CD8+，CD4+/CD8+）和尿液分泌型免疫球蛋白A（SIgA）水平；检测治疗前后肿瘤坏死因子-α（TNF-α），白细胞介素-6（IL-6），IL-8和降钙素原（PCT）等炎症因子水平。结果：经秩和检验，观察组患者临床疗效优于对照组（P<0.05）；观察组各症状评分和总分均低于对照组（P<0.01）；治疗后观察组α1-MG，β2-MG和NAG水平均低于对照组（P<0.01）；观察组CD4+，CD4+/CD8+和SIgA均高于对照组（P<0.05），CD8+低于对照组（P<0.05）；观察组TNF-α，IL-6，IL-8和PCT水平均低于对照组（P<0.01）；观察组患者生理职能、活力、情感职能和精神健康4个维度评分均高于对照组（P<0.05）；观察组在6个月随访中平均复发次数少于对照组（P<0.01），观察组复发率为37.74%，低于对照组的60.98%（χ2=5.003，P<0.05）。结论：八味肾气丸合八正散加减治疗肾虚湿热型RUTI中老年患者可减轻临床症状、减少复发，提高生活质量，保护肾功能，并具有调节免疫和抗炎效应，近期和远期疗效均优于单纯西医治疗。

Abstract

Objective:To observe the clinical efficacy of syndrome differentiation and treatment of Bawei Shenqi Wan combined with Bazhengsan to recurrent urinary tract infections (RUTI) in the middle and old age

and investigate its effects on immunity and inflammatory factors. Method:One hundred and forty eligible patients were randomly divided into control group (70 cases) and observation group (70 cases) by using SAS software. Patients in the control group got levofloxacin tablets by oral administration

0.2 g/time

2 times/days

for continuous 2 weeks. And cefalexin and trimethoprim capsules were given at 0.25 g/day when urine culture showed negative results. Based on the treatment in control group

the patients in observation group additionally got Bawei Shenqi Wan combined with Bazhengsan

1 dose/day. The treatment course was 12 weeks in both groups. Before and after treatment

scores of the main symptoms and quality of life were graded. Relapse within 6 months was recorded. And the levels of α1-microglobulin (α1-MG) and β2-microglobulin (β2-MG)

N-acetyl-β-D-glucosaminidase (NAG)

T cell subgroup (CD3+

CD4+

CD8+

CD4+/CD8+)

urine secretory immunoglobulin A (SIgA)

tumor necrosis factor-α (TNF-α)

interleukin (IL-6) and calcitonin (PCT) were detected. Result:As analyzed by rank sum test

the clinical efficacy in observation group was superior to that in the control group (P<0.05). Scores of symptoms and the total score were all lower than those in control group (P<0.01). After treatment

levels of α1-MG

β2-MG

NAG

TNF-α

IL-6

IL-8 and PCT were all lower than those in control group (P<0.01). Levels of CD4+

CD4+/CD8+and SIgA in the observation group were higher than those in the control group (P<0.05)

while level of CD8+ was lower than that in the control group (P<0.05). The scores of physiological function

vitality

emotional function and mental health in the observation group were higher than those in the control group (P<0.05). The average number of recurrence times was less than that in the control group during the 6 months' follow-up (P<0.01)

and the recurrence rate in observation group was 37.74%

lower than 60.98% in control group (χ2=5.003

P<0.05). Conclusion:Bawei Shenqi Wan combined with Bazhengsan in the treatment of recurrent urinary tract infections in the middle and old age can relieve clinical symptoms and reduce recurrence rate

improve quality of life

protect renal function and can regulate immunity and anti-inflammatory function

superior to pure western medicine in short and long-term effects.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

早期应用大陷胸汤改善急性胰腺炎重症化趋势的临床疗效

麝香通心滴丸治疗冠状动脉慢血流的疗效及对炎症因子的影响

基于16S rDNA测序探讨滋肾通关方对慢性非细菌性前列腺炎大鼠“肠-前列腺”轴的影响

大黄酒蒸前后对便秘模型小鼠肠道菌群及免疫环境的影响

基于血清代谢组学和流式细胞术探讨百药煎不同炮制品及其复方治疗溃疡性结肠炎作用机制